Investigation and development unit focused on the generation of new technologies in regenerative medicine based on advanced therapy (cell therapy, gene therapy and tissue engineering).
The IDCBIS has highly trained human talent with knowledge in advanced cell therapy, currently has a unit called Advanced Therapies Unit (UTA) responsible for research and development of stem cell-based products for use at pre-clinical scale and in clinical trials. The ATU promotes the generation of knowledge and innovation in biomedical sciences through the articulation of actors in science and technology (public sector, academia and industry).
We have a clean room that complies with GMP quality standards for the manufacture of cell therapy products.
We lead a platform for research and development of mesenchymal stromal cell-based products for pre-clinical and clinical trial use.
We promote the generation of knowledge and innovation in biomedical sciences through the articulation of actors in science and technology (public sector, academia and industry).
Projects under development
Innovation and Production
of Advanced Therapies
Product scaling
of advanced therapy
Preclinical models
for advanced therapy
Generation of spheroids for immunomodulation studies.
Extracellular vesicles for biotechnological applications
Apoptotic bodies and immunomodulation
Tissue Engineering
Bioengineering
of the skin tissue
Biological scaffolds for skin regeneration
Design, modeling and 3D printing of skeletal structures
Bioengineering
of bone tissue
Mesenchymal stromal cell encapsulation
for advanced therapy
Model generation
3D hematopoiesis
Design of instruments and technologies for biomedical investigation.
Factor extended release systems
and antibiotics for tissue engineering
Scaffolds for skin regeneration with new biomaterials
Therapies
Adoptive and Advanced
Adoptive antiviral therapy
Tumor infiltrating lymphocyte therapy
Design of devices for T-lymphocyte expansion
Engineering
Molecular and Cellular
CAR-T cell engineering
Advanced therapies
for SARS-CoV2
Effector capacity developed by "CAR T-cells" in the expansion process.
Enhanced immunotherapy based on gene engineering
CRISPR-Cas9-based disease models
Advanced Therapies Unit Group
Advanced Therapies Unit Team
Ingrid Silva Cote
Leader in Tissue Engineering Research
Bacteriologist. MSc. Ph.D
Leidy Yohana Méndez
Investigator
Bacteriologist and Clinical Laboratorian. MSc.
Ginna Michelle López
Investigator
Bacteriologist and Clinical Laboratorian. MSc (c).
Yury Katherine Herrera
Investigator
Bacteriologist and Clinical Laboratory Technician
English 
Spanish